Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The most common issues reported include nausea, vomiting, diarrhea, and constipation, which typically subside as the body adjusts to the medication
PMID: 41318657 Cell Death Dis ATP6AP1 promotes cell proliferation and tamoxifen resistance in luminal breast cancer by inducing autophagy
Phase 3 outcomes (2026): TRIUMPH-1 (May 2026, n=2,339) demonstrated 28.3% mean weight loss at 12mg weekly the largest published Phase 3 result of any GLP-1 class compound to date, exceeding tirzepatide (22.5% in SURMOUNT-1) and semaglutide (14.9% in STEP-1) at comparable timepoints
In B2B pharmaceutical sourcing, it is evaluated as a regulated raw material for permitted formulation development, analytical testing, quality control, and manufacturing-related use
US$ 20.12
US$ 26.25
US$ 27.00
US$ 27.44
US$ 26.18
)
US$ 24.58
